# Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

> **NCT06567743** · PHASE2 · RECRUITING · sponsor: **CG Oncology, Inc.** · enrollment: 325 (estimated)

## Conditions studied

- High-Risk Non-Muscle-Invasive Bladder Cancer

## Interventions

- **DRUG:** Cretostimogene Grenadenorepvec

## Key facts

- **NCT ID:** NCT06567743
- **Lead sponsor:** CG Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-16
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-12-30
- **Target enrollment:** 325 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567743, "Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06567743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*